Understand the source comparison
ARA-290 Chronic Pain: Investigational Protocols Comparison
Dosage 1–2mg subcutaneous 3× weekly 4mg subcutaneous 3× weekly 4mg subcutaneous 3× weekly for 12+ weeks Standard 4mg dose demonstrated statistical significance in Phase 2 trials; 1–2mg showed trends but didn't reach clinical endpoints Duration 4 weeks 4–8 week
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Dosage
- 1–2mg subcutaneous 3× weekly
- 4mg subcutaneous 3× weekly
- 4mg subcutaneous 3× weekly for 12+ weeks
- Standard 4mg dose demonstrated statistical significance in Phase 2 trials; 1–2mg showed trends but didn't reach clinical endpoints
- Duration
- 4 weeks
- 4–8 weeks
- 12–16 weeks
- Short-term protocols (4 weeks) show pain reduction; extended protocols correlate with measurable IENFD increases, suggesting structural repair requires longer exposure
- Target Conditions
- Mild neuropathic pain, early-stage SFN
- Moderate to severe SFN, diabetic polyneuropathy
- Chronic refractory neuropathic pain, post-chemotherapy neuropathy
- Most published data focuses on SFN; chemotherapy-induced peripheral neuropathy (CIPN) is an emerging area with limited clinical trial evidence
- Monitoring
- Pain scales (NRS, VAS) only
- Pain scales + QST (quantitative sensory testing)
- Pain scales + QST + skin biopsy IENFD at baseline and endpoint
- IENFD is the gold standard for confirming small fiber regeneration but requires invasive biopsy; QST provides functional assessment without biopsy
- Adverse Event Profile
- Injection-site reactions 10–15%
- Injection-site reactions 15–20%, no systemic AEs reported
- Similar to standard; no cumulative toxicity observed in 16-week studies
- Clean safety profile across all dosing protocols; no CNS effects, no hematologic changes, no opioid-like dependency risk
- Cost Consideration (Research Context)
- Lower peptide consumption
- Moderate consumption
- Highest consumption; requires larger peptide inventory
- Extended protocols align with tissue regeneration timelines but require sustained access to high-purity peptide
- The comparison table above reflects published clinical trial protocols and observed outcomes in ARA-290 chronic pain research. The 4mg three-times-weekly regimen represents the most studied protocol with the strongest efficacy data, but the extended 12–16 week protocols are particularly relevant for investigators studying regenerative endpoints rather than symptomatic relief alone. The distinction matters: if the goal is short-term pain reduction, a 4-week protocol may suffice; if the goal is measurable nerve fiber regeneration, the biology requires months, not weeks.